A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Coherent Biopharma (Hefei) Co., Ltd.
Institut Paoli-Calmettes
University Hospital, Ghent
University of California, Davis
Lebanese University
Massachusetts General Hospital
Kineta Inc.
Shanghai Yunying Medical Technology
Fox Chase Cancer Center
Shanghai Yunying Medical Technology
Manchester University NHS Foundation Trust
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute
The First Affiliated Hospital of Soochow University
RenJi Hospital
RenJi Hospital
Wuhan Ammunition Life-tech Co., Ltd
Provectus Pharmaceuticals
Blue Note Therapeutics
Wellmarker Bio
Revolution Medicines, Inc.
Weprom
TScan Therapeutics, Inc.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Kyunghee University Medical Center
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
University of Maryland, Baltimore
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hyperfusion
ChineseAMS
The Clatterbridge Cancer Centre NHS Foundation Trust
SpeciCare
MetiMedi Pharmaceuticals
Sun Yat-sen University
Petra Pharma
University of Aarhus
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Dalian Medical University
Shenzhen BinDeBio Ltd.
Instituto do Cancer do Estado de São Paulo
M.D. Anderson Cancer Center
KU Leuven
Critical Outcome Technologies Inc.
Xuanwu Hospital, Beijing
University of Erlangen-Nürnberg Medical School
Ottawa Hospital Research Institute
AlgoMedica, Inc.
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Southwest Hospital, China
Rigshospitalet, Denmark